Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Unveils Gx Pricing Plans, Wants to Rectify Distortion by Cutting Oral AG Price: Chuikyo
As it sets out a flurry of reform proposals on the pricing of new drugs and off-patent products, the government plans to keep intact the current rules for first generics and first biosimilars for now. However, price revision rules for…
To read the full story
Related Article
- MHLW Proposes Pricing Support for Startups: Chuikyo
November 28, 2017
- CEA-Based Price Tweak Likely to Cover Premium Portion, Not Total Price; Price Raise Also Proposed: Chuikyo
November 28, 2017
- MHLW Proposes Expansion of “Essential Drug” Category to Include Crude Drugs, Ointment Bases, Local Dental Anesthetics and More: Chuikyo
November 28, 2017
- MHLW Proposes Tacking Premiums on Total Drug Price under Cost Calculation Formula: Chuikyo
November 27, 2017
- New Price Cut Scheme for Off-Patent Meds Proposed with Mitigation Plans, but Payer Reps Say Gx Transition Too Slow: Chuikyo
November 24, 2017
- Quarterly Market Expansion Re-Pricing Pitched for 35-Plus Billion Yen Products: Chuikyo
November 24, 2017
- MHLW Proposes Post-Launch Foreign Price Adjustments: Chuikyo
November 24, 2017
- Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
- Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
REGULATORY
- MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
April 2, 2026
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…